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In recent years there has been a great deal of research within the stem cell ﬁeld which has led to the
deﬁnition and classiﬁcation of a range of stem cells from a plethora of tissues and organs. Stem cells, by
classiﬁcation, are considered to be pluri- or multipotent and have both self-renewal and multi-
differentiation capabilities. Presently there is a great deal of interest in stem cells isolated from both
embryonic and adult tissues in the hope they hold the therapeutic key to restoring or treating damaged
cells in a number of central nervous system (CNS) disorders. In this review we will discuss the role of
mesenchymal stromal cells (MSCs) isolated from human olfactory mucosa, with particular emphasis on
their potential role as a candidate for transplant mediated repair in the CNS. Since nestin expression
deﬁnes the entire population of olfactory mucosal derived MSCs, we will compare these cells to a
population of neural crest derived nestin positive population of bone marrow-MSCs.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Friedenstein was the ﬁrst to identify that single cell suspensions
of bone marrow (BM) stroma could generate colonies of adherent
ﬁbroblast-like cells in vitro (Friedenstein et al., 1968). These colony-
forming unit ﬁbroblasts (CFU-Fs) were found to be capable of
osteogenic differentiation and provided the ﬁrst evidence that
clonogenic stem cell precursors existed of the bone lineage
(Friedenstein et al., 1968, 1970). Later these stromal cells were
classiﬁed as stem cells, since single cells could transdifferentiate
intomulti-lineage cells of bone and osteogenic tissue (Friedenstein,
1980). Their eventual capability of generating the osteogenic,
chondrogenic and adipogenic mesenchymal lineages meant they
were then given the title of mesenchymal stem cells (Caplan, 1991,
Fig. 1). It was also shown that whilst they cannot make hemato-
poietic stem cells (HSCs), they do physically support them and
promote their differentiation (Dexter, 1982; Owen, 1988). Inter-
estingly, Caplan discussed the concept of cell transplantation
therapy using MSCs therapeutically, but as a source of bone and
connective tissue (Caplan,1991). This becamemore pertinent when
it was shown that MSCs only express the class I major. Barnett).
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), http://dx.doi.org/10.1016/j.histocompatibility complex (MHC-1) but not class II or co-
stimulatory molecules such as CD40, CD80 and CD86 making
them less likely to raise an immune response (Le Blanc, 2003). It has
also been suggested that due to their limited pluripotent potential,
MSCs should be re-named and termed “mesenchymal stromal
cells” to avoid the excessive promotion of their stem cell potential
(Horwitz et al., 2005; Pacini and Petrini, 2014). Therefore, in this
review the abbreviationMSC is referred to as mesenchymal stromal
cells (MSCs).1.1. MSCs and their origins
MSCs are known to be present in virtually all postnatal organs
and tissues including heart, lung umbilical cord, peripheral blood,
adipose tissue, muscle, cartilage, synovium, dental pulp, BM, tonsil,
placenta, thymus and olfactory mucosa (OM) (da Silva Meirelles
et al., 2006; Kuhn and Tuan, 2010; Lindsay et al., 2013, 2016; Xie
et al., 2015). However, whether they permanently reside in such
tissues, or can circulate in the blood or even exist in perivascular
spaces to reach different tissues is still not known (Pacini and
Petrini, 2014). By deﬁnition MSCs must i) adhere to plastic, ii) ex-
press speciﬁc cell surface markers and iii) differentiate in a multi-
potential manner along the osteogenic, chondrogenic, and
adipogenic lineages (Dominici et al., 2006). A panel of markers are
used to deﬁne MSCs including CD73 (ecto-50nucleotidase) CD90under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Differentiation of MSCs based on Caplan, 1991. MSCs have the capacity to
differentiate into osteogenic, chondrogenic and adipogenic mesenchymal lineages.
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NTR), CD44 and STRO-1. However, none of these are speciﬁc and
will also label a range of other cell types including endothelial cells,
epithelial cells, ﬁbroblasts, T cells and certain neural cell types
(Kuhn and Tuan, 2010; Xie et al., 2015). MSCs also lack expression of
CD34 (hematopoietic progenitor and endothelial cell marker),
CD45 (pan-leukocyte marker), CD11b or CD14 (monocyte and
macrophagemarkers), CD19 or CD79a (B cell markers), and HLA-DR
(marker of stimulated MSCs) (Mo et al., 2016). Initially their puri-
ﬁcation from BM was carried out by differential adherence to
plastic since only the MSCs from stroma will adhere. However,
there are now speciﬁc isolation kits available based on cell surface
antibodies and magnetic selection which can be used to highly
enrich for MSCs from a variety of different tissue sources, including
BM. To add to the complexity, MSCs share cell-surface markers and
localisation with pericytes, making their true classiﬁcation and
distinction even more complex (Crisan et al., 2008). Importantly, in
the context of their therapeutic potential, these cells are widely
available, have a high capacity to self-renew and are easily propa-
gated in culture in substantial enough numbers. However the lack
of standardised protocols for their expansion and isolation makes
results difﬁcult to interpret (Pacini and Petrini, 2014).1.2. MSCs from the human olfactory mucosa
The uniquely regenerative properties of the olfactory system
(Graziadei and Monti Graziadei, 1983) has meant that this tissue
has gained much interest for the transplant mediated repair of the
CNS (Barnett and Riddell, 2007; Lindsay et al., 2010; Roet and
Verhaagen, 2014; Tabakow et al., 2013). Some of the trans-
plantation studies have incorporated the use of the entire OM,
while others have used the puriﬁed glial cell population, known as
olfactory ensheathing cells (Li et al., 1997; Ramon-Cueto et al.,
2000). We undertook a study to identify the stem cell pop-
ulation(s) from this tissue, since many researchers were already
transplanting cells from OM into patients (Lima et al., 2006;
Mackay-Sim et al., 2008; Geraghty, 2008). We identiﬁed MSC-like
cells from the lamina propria of the human OM using CD271Please cite this article in press as: Lindsay, S.L., Barnett, S.C., Are nestin-
repair?, Neurochemistry International (2016), http://dx.doi.org/10.1016/j.puriﬁcation and selection, which we termed OM-MSCs (Lindsay
et al., 2013; Johnstone et al., 2015). Detailed comparison was
made with classical BM-derived MSCs which were isolated and
maintained using identical methods and culture conditions
(Lindsay et al., 2013; Johnstone et al., 2015). We demonstrated that
the OM-MSCs adhered to plastic, expressed classical markers and
differentiated into bone and fat lineages in a similar manner to BM-
MSCs. Furthermore, using a micro (mi)RNA array we showed that
they were 64% homologous with a similar core subset of miRNAs
(Lindsay et al., 2016). We and others have also shown that while
they were identical in their expression of a panel of CD markers, a
greater proportion of OM-MSCs expressed nestin immunoreac-
tivity; 100% of OM-MSCs express nestin compared to around 50% of
BM-MSCs (Lindsay et al., 2010; Johnstone et al., 2015; Delorme
et al., 2010, Fig. 2, Table 1). The relevance of nestin-positive MSCs
within the BM is now being evaluated by researchers. Nestin is a
class VI intermediate ﬁlament protein which was originally iden-
tiﬁed as a stem cell marker for neuroepithelial cells (Lendah et al.,
1990), although, it has been reported to label a range of cells from
neural stem cells, ﬁbroblasts and reactive glia (Kishaba et al., 2010;
Toft et al., 2013; Xie et al., 2015). Table 1 summarises the compar-
ative differences reported to date on OM-MSCs and BM-MSCs. Since
OM-MSCs have only recently been identiﬁed, very few direct
comparisons of their biological properties to BM-MSCs have been
reported. Although, we have directly compared the two types of
MSCs abilty to promote CNS myelination in vitro in the table,
comparative data on myelination potential in vivo is limited. BM-
MSCs have been shown to increase the number of oligodendro-
cytes, and enhance remyelination in EAE but similar data for OM-
MSCs has not been published (see review of Cohen, 2013).
1.3. Nestin-positive OM- and BM-MSCs
Interestingly, a subpopulation of BM-MSCs have also been re-
ported to express nestin (Tondreau et al., 2004; Wiese et al., 2004)
and more detailed studies demonstrated that the nestin-positive
MSCs are similar to early progenitor cells that are able to self-
renew and differentiate into bone, fat and adipose (Mendez-
Ferrer et al., 2010). These early progenitors have been hypoth-
esised to be “mesodermal progenitor cells” or MPCs by other re-
searchers (Petrini et al., 2009; Pacini and Petrini, 2014). The nestin-
positive MSCs have been shown to co-localize with HSCs support-
ing their maintenance and homing (Isern and Mendez-Ferrer,
2011). Using transgenic mice that express the regulatory elements
of the nestin-promotor (Nes-GFP) it was demonstrated that the
nestin-positive MSC subpopulation originate from the neural crest
and have special HSC niche functions, while the nestin-negative
MSCs originate from the mesoderm and give rise to bone and
cartilage (Isern et al., 2014). Other epithelial tissues have also been
suggested to contain neural crest derived mesenchymal pro-
genitors including the human oral mucosa (Davies et al., 2010), oral
gingivae (Xu et al., 2013), dental pulp tissue (Volponi et al., 2010)
and airway epithelium (Ortega-Martínez et al., 2015). Furthermore,
nestin-positive MSCs were identiﬁed in airway epithelium within
the perivascular areas and in connective tissue that is in close
proximity to the airway epithelium (Ortega-Martínez et al., 2015).
These authors suggest that these MSCs circulate in the blood-
stream, transmigrate through blood vessels and localize in the
epithelium to participate in its turnover by being able to generate
several different types of lung tissues. This could be a general
feature of many different types of mucosa that exist throughout the
body, where rapid turnover of cells is required after damage or
during normal cell turnover. The importance of isolating nestin-
positive neural crest derived MSCs for therapy over nestin-
negative MSCs is not yet fully known. Moreover, the variouspositive mesenchymal stromal cells a better source of cells for CNS
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Fig. 2. Differential expression of nestin on OM-MSCs and BM-MSCs (nestin stained green; nuclei stained blue DAPI). Scale bar represents 50 mm. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1







Express most classical MSC markers with difference reported only in:
Nestin þþþ þ Delorme et al., 2010; Lindsay et al., 2013; Di Trapani et al., 2013;
Johnstone et al., 2015; Rui et al., 2016
CD271 þ þ Lindsay et al., 2013; Johnstone et al., 2015
CD200, CD146  þ Delorme et al., 2010; Wetzig et al., 2013
Micro RNA expression
miR-differentially expressed:
Lindsay et al., 2016, Tome et al., 2011
140-5p; 10b-5p; 335-5p; 3665; 3188; 2861; 4281; 762; 874; 1915; 638; 424-5p;
140-5p; 224-5p; 140-3p; 939; 1225-5p.
 þ




Nestin, CXCL12, CD90, S100A4, CD40 þþþ þ Delorme et al., 2010; Johnstone et al., 2015; Lindsay et al., 2016;
Wetzig et al., 2013
CD73 þ þþþ Johnstone et al., 2015
Chemokines
CXCL12 þþþ þ Lindsay et al., 2016
IL-6, IL-8, CCL2, IL-10, TGF-b þ þþþ Lindsay et al., 2016; Rui et al., 2016
Biological properties
Clonal efﬁciency, Proliferation þþþ  Delorme et al., 2010; Lindsay et al., 2013
Osteogenesis, Adipogenesis þ þþþ Delorme et al., 2010; Lindsay et al., 2013; Wetzig et al., 2013
Chondrogenesis  þþþ Delorme et al., 2010; Lindsay et al., 2013; Wetzig et al., 2013
T-cell proliferation   Di Trapani et al., 2013; Rui et al., 2016
CNS Myelination (in vitro) þþþ þ/ Lindsay et al., 2013; Lindsay et al., 2016
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have been mainly identiﬁed from rodent studies, and it is yet not
known if similar cells exist in the human BM; although several
recent reports have shown that the human BM niche contains
nestin-positive MSCs (Crisan et al., 2008; Matsuoka et al., 2015;
Pacini and Petrini, 2014; Schajnovitz et al., 2011). These data
corroborate our own published results which demonstrate that
around 50% of puriﬁed BM-MSC express nestin immunoreactivity
(Johnstone et al., 2015).
We have shown that OM-MSCs, which are 100% nestin-positive
better promoted in vitro CNS myelination when compared to BM-
MSCs (Lindsay et al., 2013) and that they also moved microglia to
an anti-inﬂammatory phenotype, which correlated with their
secretion of less pro-inﬂammatory cytokines (Lindsay et al., 2016).
In addition, others have shown different differentiation capabilities
of nestin-positive neural crest derived MSCs, and have shown that
they too have beneﬁcial immunoregulatory function over immune
cells when compared tomesodermal derivedMSCs (Xu et al., 2013).
Therefore, it may be that there exists a subpopulation of neural
crest derived MSCs in a variety of different tissues that are morePlease cite this article in press as: Lindsay, S.L., Barnett, S.C., Are nestin-
repair?, Neurochemistry International (2016), http://dx.doi.org/10.1016/j.suited to regenerative medicine.
1.4. The role of CXCL12 in the bone marrow niche
The BM contains many cell types including HSCs, endothelial
cells, osteoblasts, osteoprogenitors, chemokine (CeXeC motif)
ligand 12 (CXCL12)-abundant reticular (CAR) cells and
nestinþ NG2þ MSCs (which have been classiﬁed primarily based
on the availability of a speciﬁc Cre-recombinase mouse or related
reporter mouse which include Lepr-Cre (Ding et al., 2012), Prx1-Cre
(Greenbaum et al., 2013), Nestin-Cre (Isern et al., 2014; Mendez-
Ferrer et al., 2010), CXCL12-GFP (Omatsu et al., 2010; Sugiyama
and Nagasawa, 2012). Cells were thus identiﬁed as nestin-GFPdim
and nestin-GFPbright in one tracing experiment (Isern and Mendez-
Ferrer, 2011) and nestin-LepRþ MSCs from a different reporter
mouse. Moreover, deﬁnition of these various cell types does not
exclude overlapping phenotype between each of these classiﬁed
populations and so none of the deﬁned cell types are exclusive from
each other (Hoggatt et al., 2016; Coste et al., 2015; Ding et al., 2012;
Greenbaum et al., 2013; Sugiyama and Nagasawa, 2012). It is wellpositive mesenchymal stromal cells a better source of cells for CNS
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Fig. 3. Schematic illustrating the various cell types in the rodent bone marrow niche
including the range of cells secreting CXCL12 based on Boulais and Frenette, 2015.
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important role within the human and rodent BM in controlling HSC
and progenitor function (Isern et al., 2014; Schajnovitz et al., 2011).
Our own investigations have also revealed an important role for
CXCL12 in human OM-MSC biology. OM-MSCs under the regulation
of miR140-5p secrete more CXCL12 than BM-MSCs which is
responsible for promoting rat CNS myelination in vitro to a greater
extent than BM-MSCs (Lindsay et al., 2013, 2016). In the BM, CXCL12
has a range of HSC regulatory functions from retention (blocking
their differentiation andmigration) to quiescence and repopulation
activity (Greenbaum et al., 2013; Schajnovitz et al., 2011). BM-MSCs
take part in the host defence by rapidly releasing CXCL12 into the
circulation, which results in the mobilisation of progenitor cells
(Kollet et al., 2003; Petit et al., 2002).
In the mouse BM three perivascular stromal cell populations
that express high levels of CXCL12 have been identiﬁed: CXCL12-
abundant reticular (CAR) cells, nestin-GFPþ stromal cells, and
lepRþ stromal cells (Fig. 3). These stromal cell populations are
deﬁned by transgene expression using deﬁned stromal-speciﬁc
promoters, and as discussed above, it is likely that there is
considerable overlap (Anthony and Link, 2014). Other cells within
the BM have been shown to secrete CXCL12 including, osteoblasts,
and endothelial cells (Ding et al., 2012; Sugiyama and Nagasawa,
2012). However, more recent detailed analysis using cell type
speciﬁc promoters to knock out CXCL12 expression has shown that
HSC maintenance and mobilisation was dependent upon nestin-
positive mesenchymal progenitors (Greenbaum et al., 2013).Please cite this article in press as: Lindsay, S.L., Barnett, S.C., Are nestin-
repair?, Neurochemistry International (2016), http://dx.doi.org/10.1016/j.Indeed deletion of nestin positive MSCs from the bone marrow has
been shown to cause a dramatic expansion of HSCs due to a
reduction in CXCL12 levels (Arranz et al., 2014). What this data
highlights is an important role for CXCL12 secretion by nestin-
positive MSCs and that such MSCs are central participants in HSC
regulation.
It is also thought that within the BM microenvironment pop-
ulations of cells exist which have differing roles in regulating the
biology of HSCs (Boulais and Frenette, 2015; Coste et al., 2015). The
endosteal niche is mainly composed of osteoblasts, osteoclasts,
adipocytes, CAR cells, stromal cells, nestinþ MSCs, which together
maintain HSCs in a quiescent state. In contrast, the vascular niche
which is located near to BM sinusoid vessels is composed of peri-
vascular (nestinþ) stromal cells, CAR cells and the peripheral glia,
Schwann cells. The former two cell types favouring HSC activation
and recruitment, with the latter involved in HSC maintenance.
Interestingly, there has been a report to suggest that human OM-
MSCs can also promote the in vitro survival, proliferation and dif-
ferentiation of human HSCs (Diaz-Solano et al., 2012). Thus it is
possible then that nestinþ MSCs from the OM are similar to these
nestinþ MSCs from the BM or are in fact the same neural crest
derived source of MSCs. Further experiments, including fate map-
ping are required to fully elucidate whether OM-MSCs are indeed
neural crest derived although it is tempting to speculate that they
are, as it has been shown using reporter mice, that olfactory
ensheathing cells (Barraud et al., 2010), olfactory receptor neurons,
sustentacular cells and the basal stem cells from the olfactory
epithelium after injury, originate from the neural crest (Suzuki
et al., 2013).
1.5. MSCs for the treatment of CNS disease/injury
BM-MSCs have long been considered as candidates for the
transplant-mediated repair of the injured or diseased CNS. They
have already been evaluated in a number of clinical trials for the
treatment of a range of CNS disorders including amyotrophic lateral
sclerosis (Mazzini et al., 2003, 2009, 2012; Oh and N€or, 2015);
progressive supranuclear palsy (Giordano et al., 2014); cerebral
palsy in children (Wang et al., 2013); ischaemic heart failure
(Mathiasen et al., 2015; Rodrigo et al., 2013); myocardial infarction
(Hare et al., 2009); knee osteoarthritis (Vega et al., 2015); acute
respiratory distress syndrome (Wilson et al., 2015) and Crohn's
disease (Duijvestein et al., 2010). However most of these studies are
phase I and have only shown safety of administration rather than
efﬁcacy.
Since MSCs are thought to have an immunomodulatory role,
they have also been proposed for the treatment of the immune
mediated demyelinating disease, Multiple Sclerosis (MS). In
experimental autoimmune encephalomyelitis (EAE), an animal
model of MS, MSC transplantation has been shown to have prom-
ising beneﬁcial effects, using both syngeneic cells (Gerdoni et al.,
2007; Karussis et al., 2008) as well as human cells (Bai et al.,
2009; Rafei et al., 2009). These include a reduction in demyelin-
ation, axonal loss, leucocyte inﬁltration, inhibition of T cell prolif-
eration, and macrophage/microglia activation. The beneﬁcial
effects of BM-MSC transplantation in EAE are generally attributed
to immunomodulatory effects in the periphery, although they may
also migrate into the CNS to secrete soluble neuroprotective factors
that support endogenous tissue repair and remyelination (Bai et al.,
2009; Freedman et al., 2010; Pluchino and Martino, 2008).
Culturing BM-MSCs withmicroglia has indicated that they promote
a switch in LPS-activated microglia from a detrimental phenotype
to one more beneﬁcial (Giunti et al., 2012). Moreover, promising
effects have been seen in human trials of autologous trans-
plantation of BM-MSCs in secondary progressive patientspositive mesenchymal stromal cells a better source of cells for CNS
neuint.2016.08.001
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from structural, functional, and physiological improvement which
strongly supports their future use as treatment in MS (Bonab et al.,
2012; Connick et al., 2012; Harris et al., 2012; Uccelli et al., 2013;
Llufriu et al., 2014).
While it has been known for numerous years that the human
olfactory tissue contains multipotent stem cells which were typi-
cally from the basal layer in the epithelium, or from the olfactory
bulb (Goldstein et al., 1968; Roisen et al., 2001; Murrell et al., 2005,
2008; Marshall et al., 2006), it was only recently that mesenchymal
like stromal cells were identiﬁed from the lamina propria of the OM
(Tome et al., 2009; Delorme et al., 2010), and since then OM derived
MSCs have only been described in a handful of reports detailing
their use in tissue repair. For example, a study was carried out using
human MSCs from the OM in a mouse model of early onset
sensorineural hearing loss (Pandit et al., 2011). Here olfactoryMSCs,
prepared as described by Delorme et al. (2010), were injected into
the cochlea of A/J mice which exhibit early-onset progressive
sensorineural hearing loss. OM-MSC transplantation was seen to
prevent hearing loss as assessed by response to both click and pure
tone stimuli suggesting they protect against loss of auditory func-
tion. Other studies have been reported on the repair potential of
OM-MSCs using mice with hippocampal lesions created by the
injection of a NMDA agonist. In these mice, transplantation of OM-
MSCs restored learning and memory using behavioural testing
when compared to non-transplanted control mice (Nivet et al.,
2011). A recent study using mouse derived OM-MSCs also
demonstrated that they could suppress arthritis onset in a mouse
model of collagen-induced arthritis (Rui et al., 2016).
Furthermore, it is possible that in experiments which use
dissociated olfactory mucosa cells, OM-MSCs may be present in the
heterogeneous cell mix (Lima et al., 2006, 2010;Murrell et al., 2008;
Chhabra et al., 2009; Granger et al., 2012; Iwatsuki et al., 2016;
Wang et al., 2016). However, there is no detailed analysis of the
cellular composition of these cellular mixes or which cell type(s)
dominate or in fact which cell type has reparative properties.
Indeed a spinal cord injured patient who received a transplant of
un-puriﬁed olfactory mucosa was found to develop an intra-
medullary spinal cordmass 8 years post-surgery, composed of cysts
lined with respiratory epithelium (Dlouhy et al., 2014). Therefore,
the use of un-puriﬁed olfactory mucosal cells cannot be directly
compared to puriﬁed OM-MSCs and indeed highlights the impor-
tance of transplanting cells which are fully characterised. In terms
of therapeutic paradigms it is vital that any cell type that is to be
transplanted is fully characterised. Unfortunately, due to the tech-
nical variability in harvesting and growing cells from both BM and
OM it is difﬁcult to compare data across experiments. However,
from the limited studies and our own data, which demonstrates
OM-MSCs promote rat CNSmyelination in vitro (Lindsay et al., 2010,
2016) and in vivo (Lindsay et al., submitted), we would postulate
they may be an alternative candidate for the treatment in MS or
other demyelinating diseases/injuries. Similarly they may be ad-
vantageous where neuroprotection or neurite outgrowth is
important for repair eg retinitis pigmentosa, age-related macular
degeneration, ALS, and stroke. The identiﬁcation that OM-MSCs
secrete higher levels of the chemokine CXCL12 than BM-MSCs
(Lindsay et al., 2016), which we and others have shown to be
important in augmenting endogenous myelination (Maysami et al.,
2006; Lindsay et al., 2013, 2016; Zilkha-Falb et al., 2016) also adds to
the desirability as a candidate cell for transplantation. Lastly as
MSCs are known to home to damaged tissue (Laroni et al., 2013;
Eseonu and De Bari, 2015) and secrete a plethora of pro-repair
factors, their use as a treatment is more beneﬁcial than applica-
tion of a chemokine alone (Allers et al., 2014; Joyce et al., 2010;
Laroni et al., 2013).Please cite this article in press as: Lindsay, S.L., Barnett, S.C., Are nestin-
repair?, Neurochemistry International (2016), http://dx.doi.org/10.1016/j.In conclusion, we feel that nestin-positive OM-MSCs may be
derived from the neural crest, and are an easily accessible source of
cells whichmay be therapeutically advantageous over BM-MSCs for
the treatment of demyelinating conditions such as MS.
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